General Electric Co
Change company Symbol lookup
Select an option...
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
BTBT Bit Digital Inc
RUMBW Rumble Equity Warrant Exp 16th Sept 2027 *W EXP 09/16/2027
RSLS ReShape Lifesciences Inc
BWA Borgwarner Inc
CSCO Cisco Systems Inc
Go

Industrials : Industrial Conglomerates | Large Cap Value
Company profile

General Electric Company is an industrial company. The Company operates through its industrial segments, Power, Renewable Energy, Aviation and Healthcare, and its financial services segment, Capital. Its segments include Power, which serves power generation, industrial, government and other customers with products and services related to energy production; Renewable Energy, which provides solutions for renewable energy; Aviation, which includes commercial and military aircraft engines, and integrated digital components, electric power and mechanical aircraft systems; Healthcare, which provides healthcare technologies in medical imaging, digital solutions, patient monitoring and diagnostics, and drug discovery, and Capital, which is a financial services division. Its products include commercial and military aircraft engines and systems; healthcare systems and pharmaceutical diagnostics; wind and other renewable energy generation equipment; nuclear and other power generation equipment.

Postmarket

Last Trade
Delayed
$64.35
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$64.35
Day's Change
-0.12 (-0.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
66.16
Day's Low
64.21
Volume
(Heavy Day)
Volume:
10,453,129

10-day average volume:
7,173,373
10,453,129

Merck Announces Fourth-Quarter 2022 Dividend

12:40 pm ET July 26, 2022 (BusinessWire) Print

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company's common stock for the fourth quarter of 2022. Payment will be made on Oct. 7, 2022, to shareholders of record at the close of business on Sept. 15, 2022.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005947/en/

SOURCE: Merck & Co., Inc.">

Media:
Johanna Herrmann, (617) 216-6029
Melissa Moody, (215) 407-3536

Investor:
Peter Dannenbaum, (908) 740-1037
Steven Graziano, (908) 740-6582
comtex tracking

COMTEX_410997386/1006/2022-07-26T12:40:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.